AU2020232246B2 - Methods of treating disease with levoketoconazole - Google Patents

Methods of treating disease with levoketoconazole Download PDF

Info

Publication number
AU2020232246B2
AU2020232246B2 AU2020232246A AU2020232246A AU2020232246B2 AU 2020232246 B2 AU2020232246 B2 AU 2020232246B2 AU 2020232246 A AU2020232246 A AU 2020232246A AU 2020232246 A AU2020232246 A AU 2020232246A AU 2020232246 B2 AU2020232246 B2 AU 2020232246B2
Authority
AU
Australia
Prior art keywords
pharmaceutically acceptable
acceptable salt
levoketoconazole
subject
metformin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020232246A
Other languages
English (en)
Other versions
AU2020232246A1 (en
Inventor
Fredric Cohen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Strongbridge Dublin Ltd
Original Assignee
Strongbridge Dublin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72338256&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2020232246(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Strongbridge Dublin Ltd filed Critical Strongbridge Dublin Ltd
Publication of AU2020232246A1 publication Critical patent/AU2020232246A1/en
Application granted granted Critical
Publication of AU2020232246B2 publication Critical patent/AU2020232246B2/en
Priority to AU2025204382A priority Critical patent/AU2025204382A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2020232246A 2019-03-04 2020-03-02 Methods of treating disease with levoketoconazole Active AU2020232246B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025204382A AU2025204382A1 (en) 2019-03-04 2025-06-12 Methods of treating disease with levoketoconazole

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962813399P 2019-03-04 2019-03-04
US62/813,399 2019-03-04
PCT/US2020/020644 WO2020180784A1 (en) 2019-03-04 2020-03-02 Methods of treating disease with levoketoconazole

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025204382A Division AU2025204382A1 (en) 2019-03-04 2025-06-12 Methods of treating disease with levoketoconazole

Publications (2)

Publication Number Publication Date
AU2020232246A1 AU2020232246A1 (en) 2021-10-07
AU2020232246B2 true AU2020232246B2 (en) 2025-03-20

Family

ID=72338256

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020232246A Active AU2020232246B2 (en) 2019-03-04 2020-03-02 Methods of treating disease with levoketoconazole
AU2025204382A Pending AU2025204382A1 (en) 2019-03-04 2025-06-12 Methods of treating disease with levoketoconazole

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025204382A Pending AU2025204382A1 (en) 2019-03-04 2025-06-12 Methods of treating disease with levoketoconazole

Country Status (10)

Country Link
US (5) US11020393B2 (https=)
EP (1) EP3934649A4 (https=)
JP (2) JP7574204B2 (https=)
KR (2) KR102950333B1 (https=)
CN (1) CN113710250A (https=)
AU (2) AU2020232246B2 (https=)
BR (1) BR112021017561A2 (https=)
CA (1) CA3132319A1 (https=)
IL (1) IL286099A (https=)
WO (1) WO2020180784A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7574204B2 (ja) * 2019-03-04 2024-10-28 ストロングブリッジ ダブリン リミテッド レボケトコナゾールによる疾患の処置方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006204334B2 (en) * 2005-01-10 2012-02-23 Cortendo Ab (Publ) Methods and compositions for treating diabetes, metabolic syndrome and other conditions
AU2007303219A1 (en) * 2006-10-02 2008-04-10 Cortendo Ab (Publ) Ketoconazole enantiomer in humans
TWI690521B (zh) * 2014-04-07 2020-04-11 美商同步製藥公司 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
WO2016048984A1 (en) * 2014-09-25 2016-03-31 Cortendo Ab (Publ) Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole
US11261157B2 (en) * 2016-12-08 2022-03-01 Novatarg, Inc. Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy
US10512667B2 (en) * 2017-06-27 2019-12-24 The Regents Of The University Of Michigan Compositions and methods for treating conditions related to adrenocortical activity and/or excessive steroid production
JP7574204B2 (ja) * 2019-03-04 2024-10-28 ストロングブリッジ ダブリン リミテッド レボケトコナゾールによる疾患の処置方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Schwartz et al., 2008, Clinical Therapeutics, 30(6), pp. 1081-1088. (Year: 2008). *

Also Published As

Publication number Publication date
AU2025204382A1 (en) 2025-07-03
JP7574204B2 (ja) 2024-10-28
KR20260049881A (ko) 2026-04-14
US20200397781A1 (en) 2020-12-24
KR20210135278A (ko) 2021-11-12
US20240148724A1 (en) 2024-05-09
US11278547B2 (en) 2022-03-22
JP7801408B2 (ja) 2026-01-16
WO2020180784A1 (en) 2020-09-10
KR102950333B1 (ko) 2026-04-08
IL286099A (en) 2021-10-31
BR112021017561A2 (pt) 2021-11-09
US11020393B2 (en) 2021-06-01
JP2025026838A (ja) 2025-02-26
EP3934649A1 (en) 2022-01-12
US20210267970A1 (en) 2021-09-02
EP3934649A4 (en) 2022-11-23
US11903940B2 (en) 2024-02-20
US20220387425A1 (en) 2022-12-08
US20250387389A1 (en) 2025-12-25
CN113710250A (zh) 2021-11-26
JP2022522873A (ja) 2022-04-20
US12377096B2 (en) 2025-08-05
CA3132319A1 (en) 2020-09-10
AU2020232246A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
JP2021020902A5 (https=)
CN107249591B (zh) 固体药物配制品及其制备方法
US20090175942A1 (en) Solid Dosage Form of Olmesartan Medoxomil And Amlodipine
JP2021525768A (ja) Ｅｇｆｒ変異に関連する癌の治療組成物及び治療方法
CA2846454A1 (en) Synergistic combinations of pi3k- and mek-inhibitors
US20250387389A1 (en) Methods of treating disease with levoketoconazole
EP2762141A1 (en) Drug for the treatment of allergic rhinitis comprising pgd2 antagonist and histamine antagonist
US20220193071A1 (en) Methods for cancer therapy
US20130023496A1 (en) Combination Therapy Comprising A CCR5 Antagonist, A HIV-1 Protease Inhibtior and a Pharmacokinetic Enhancer
EP3025711B1 (en) Medicine for preventing or treating hypertension
US20240374600A1 (en) Methods and compositions for treating cancer
CN102836161A (zh) 一种以奥美沙坦酯与苯磺酸氨氯地平及氢氯噻嗪混合组成的药物的复方制剂
SG190326A1 (en) Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
HK40062461A (en) Methods of treating disease with levoketoconazole
US20210220300A1 (en) Methods of treating disease with dichlorphenamide
US20210100760A1 (en) Methods of treating disease with dichlorphenamide
HK40030002B (zh) 癌症疗法
GB2471970A (en) Composition comprising olmesartan medoxomil, amlodipine and hydrochlorothiazide

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)